Reviewing Assembly Biosciences (ASMB) & Supernus Pharmaceuticals (SUPN)
Assembly Biosciences (NASDAQ: ASMB) and Supernus Pharmaceuticals (NASDAQ:SUPN) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, valuation, risk, profitabiliy, earnings and analyst recommendations.
This table compares Assembly Biosciences and Supernus Pharmaceuticals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Volatility and Risk
Assembly Biosciences has a beta of 0.79, meaning that its share price is 21% less volatile than the S&P 500. Comparatively, Supernus Pharmaceuticals has a beta of 1.31, meaning that its share price is 31% more volatile than the S&P 500.
This is a breakdown of current ratings for Assembly Biosciences and Supernus Pharmaceuticals, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Assembly Biosciences currently has a consensus target price of $35.00, indicating a potential upside of 53.24%. Supernus Pharmaceuticals has a consensus target price of $48.33, indicating a potential upside of 17.74%. Given Assembly Biosciences’ stronger consensus rating and higher probable upside, analysts plainly believe Assembly Biosciences is more favorable than Supernus Pharmaceuticals.
Institutional and Insider Ownership
68.9% of Assembly Biosciences shares are owned by institutional investors. Comparatively, 91.2% of Supernus Pharmaceuticals shares are owned by institutional investors. 19.6% of Assembly Biosciences shares are owned by company insiders. Comparatively, 6.7% of Supernus Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Earnings & Valuation
This table compares Assembly Biosciences and Supernus Pharmaceuticals’ revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|Assembly Biosciences||$684,369.00||578.90||-$47.84 million||($2.74)||-8.34|
|Supernus Pharmaceuticals||$252.59 million||8.21||$81.75 million||$1.95||21.05|
Supernus Pharmaceuticals has higher revenue and earnings than Assembly Biosciences. Assembly Biosciences is trading at a lower price-to-earnings ratio than Supernus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Supernus Pharmaceuticals beats Assembly Biosciences on 9 of the 13 factors compared between the two stocks.
About Assembly Biosciences
Assembly Biosciences, Inc. is a biotechnology company. The Company is engaged in developing two platform programs, such as a class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection, and a class of oral synthetic live therapeutics, which are designed to restore health to a dysbiotic microbiome. It has discovered various core protein Allosteric Modulators (CpAMs), which are small molecules that directly target and allosterically modulate the HBV core (HBc) protein. Its Microbiome Program consists of an integrated platform that includes a strain identification and selection process, methods for strain isolation and growth under current good manufacturing practice conditions, and a delivery system, GEMICEL, which allows for targeted oral delivery of live biologic and conventional therapies to the lower gastrointestinal (GI) tract. The lead product candidate from this platform, AB-M101, is in development for the treatment of clostridium difficile-infections.
About Supernus Pharmaceuticals
Supernus Pharmaceuticals, Inc. is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company offers Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended-release topiramate), its two treatments for patients with epilepsy. In addition, it is developing multiple product candidates in psychiatry to address unmet medical needs and market opportunities for the treatment of impulsive aggression (IA) and for the treatment of attention deficit hyperactivity disorder (ADHD). It is developing SPN-810 (molindone hydrochloride) to treat IA in patients having ADHD. It is developing SPN-812 (viloxazine hydrochloride) as a candidate to treat patients having ADHD. The Company’s neurology portfolio consists of Oxtellar XR and Trokendi XR, which are the first once-daily extended release oxcarbazepine and topiramate products, respectively, indicated for epilepsy in the United States market.
Receive News & Ratings for Assembly Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Assembly Biosciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.